Management of peripheral arterial disease patients: Comparing the ACC/AHA and TASC-II guidelines

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2509-2522

  Mohler III, Emile R ^a   Giri, Jay ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiplatelet therapy; Claudication; Guidelines; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFLOMEDIL; CARNITINE; CILOSTAZOL; CLOPIDOGREL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FOLIC ACID; GEMFIBROZIL; GINKGO BILOBA EXTRACT; HEMOGLOBIN A1C; HEPARIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NAFTIDROFURYL; NICOTINIC ACID; PENTOXIFYLLINE; PLACEBO; PROSTANOID; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; WARFARIN;

ANKLE BRACHIAL INDEX; ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CRITERION VARIABLE; DATA BASE; DIABETES MELLITUS; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FOOT CARE; GLYCEMIC CONTROL; GROUP THERAPY; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LIMB ISCHEMIA; MEDLINE; MONOTHERAPY; NICOTINE REPLACEMENT THERAPY; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; THROMBOSIS; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; WALKING SPEED;

HUMANS; LIFE STYLE; PERIPHERAL VASCULAR DISEASES; PRACTICE GUIDELINES AS TOPIC; SMOKING CESSATION;

EID: 53349177231     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802274379     Document Type: Review

References (75)

1. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in out-patients with atherothrombosis. JAMA 2006;295:180-9
2. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Eng] J Med 1992-326:381-6
3. McDermott MM, Greenland P, Liu K, et al. The ankle bracbial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med. 2002;136:873-83
4. Mohler ER. Peripheral arterial disease: identification and implications. Arch Intern Med 2003;163:2306-14
5. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-15
6. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43
7. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24
8. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-81
9. McDermott MM, Fried L, Simonsick E, et al. Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the women's health and aging study. Circulation 2000;101:1007-12
10. Hackam DG, Tan MK, Lin PJ, et al. Supporting a call to action for peripheral artery disease: insights from two prospective clinical registries. Eur J Vasc Surg 2006;44:776-81
11. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease Gower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463-654
12. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl 1):S1-75
13. Agency for Health Care Policy and Research. Heart Failure: evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. In: Services HaH, ed. Bethesda, MD: National Library of Medicine June 1994
14. Criqui MH. Peripheral arterial disease - epidemiological aspects. Vasc Med 2001;6:3-7
15. Ness J, Aronow WS, Ahn C. Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc 2000;48:312-14
16. Novo S, Avellone G, Di Garbo V, et al. Prevalence of risk factors in patients with peripheral arterial disease. A clinical and epidemiological evaluation. Int Angiol 1992;11:218-29
17. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59
18. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng] J Med 1998;339:1349-57
19. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003;107:1848-51
20. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9
21. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
23. Giri J, McDermott MM, Greenland P, et al. Statin use and functional decline in patients with and without peripheral arterial disease. J Am Coll Cardiol 2006;47:998-1004
24. Mohler ER, 3rd Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481-6
25. Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003;114:359-64
26. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-18
27. Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991;83:438-47
28. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation. 2004;110:3512-17
29. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 2003;289:2560-72
30. Narins CR, Zareba W, Moss AJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004;164:440-6
31. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:1731-8
32. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-8
33. Fogoros RN. Exacerbation of intermittent claudication by propranolol. N Engl J Med 1980;302:1089
34. Ingram DM, House AK, Thompson GH, et al. Beta-adrenergic blockade and peripheral vascular disease. Med J Aust 1982;1:509-11
35. Smith RS, Warren DJ. Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication. J Cardiovasc Pharmacol 1982;4:2-4
36. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769-76
37. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
38. Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006;144:660-4
39. Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006;296:2720-6
40. Loon E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77
41. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
42. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998;3:257-60
43. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39
44. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-8
45. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
46. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-27
47. Mohler ER, 3rd. Atherothrombosis- wave goodbye to combined anticoagulation and antiplatelet therapy? N Engl J Med 2007;357:293-6
48. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206
49. Clement DL, Boccalon H, Dormandy J, et al. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis). Int Angiol 2000;19:97-125
50. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995;274:975-80
51. Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602-9
52. Hiatt WR, Wolfel EE, Meier RH, et al. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 1994;90:1866-74
53. Regensteiner JG. Exercise in the treatment of claudication: assessment and treatment of functional impairment. Vasc Med 1997;2:238-42
54. Regensteiner JG, Meyer TJ, Krupski WC, et al. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997;48:291-300
55. Garg PK, Tian L, Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation 2006;114:242-8
56. Regensteiner JG, Ware JE, McCarthy WJ, Jr, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002;50:1939-46
57. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998;339:1810-16
58. Lehert P, Comte S, Gamand S, et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994;23(Suppl3):S48-52
59. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996;155:1053-9
60. Wilson AM, Harada R, Nair N, et al. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007;116:188-95
61. McDermott MM, Guralnik. JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003;107:757-61
62. Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006;144:660-4
63. Leizorovicz A, Becker F, on behalf of the Limbs International Medicinal Buflomedil (LIMB) Study Group. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. Circulation 2008;117:816-22
64. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med 1998;338:1105-11
65. Weaver FA, Comerota AJ, Youngblood M, et al. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity. J Vasc Surg 1996;24:513-21
66. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:609-26S
67. Balzer K, Bechara G, Bisler H, et al. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost. Int Angiol 1991;10:229-32
68. The Ischemia Cronica degli Arti Inferiori (ICAI) Study Group. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. Ann Intern Med 1999;130:412-21
69. 1 versus pentoxifylline therapy in chronic arterial occlusive disease- a controlled randomised multicenter study. Vasa Suppl 1989;28:44-9
70. UK Severe Limb Ischaernia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. Eur J Vasc Surg 1991;5:511-16
71. Bianchi C, Montalvo V, Ou HW, et al. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg 2007;21:163-6
72. Mukherjee D, Lingam P, Chetcuti S, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation 2002;106:1909-12
73. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-22
74. Smaha LA. The American Heart Association Get With The Guidelines program. Am Heart J 2004; 148(5 Suppl): S46-8
75. Hirsch AT, Murphy TP, Lovell MB, et al. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation 2007;116:2086-94